Great Lakes Advisors LLC Buys 2,975 Shares of United Therapeutics Corporation $UTHR

Great Lakes Advisors LLC boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 194.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,503 shares of the biotechnology company’s stock after buying an additional 2,975 shares during the quarter. Great Lakes Advisors LLC’s holdings in United Therapeutics were worth $1,888,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of UTHR. Chung Wu Investment Group LLC acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at $29,000. WealthCollab LLC lifted its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its position in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. Wilmington Savings Fund Society FSB boosted its position in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its stake in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $429.25, for a total value of $9,658,125.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last 90 days, insiders sold 566,864 shares of company stock valued at $269,514,607. Corporate insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Royal Bank Of Canada lifted their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research note on Wednesday, October 29th. Wells Fargo & Company raised their target price on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Finally, UBS Group lifted their price target on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $509.50.

United Therapeutics Stock Up 0.4%

United Therapeutics stock opened at $469.49 on Friday. The business’s 50-day simple moving average is $487.26 and its 200 day simple moving average is $421.02. The stock has a market cap of $20.22 billion, a price-to-earnings ratio of 17.79, a P/E/G ratio of 2.49 and a beta of 0.84. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same quarter last year, the firm earned $6.39 EPS. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. As a group, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.